Sanofi may win U.S. approval of $3 billion eczema drug by March

September 26, 2016 7:24 AM

1 0

Sanofi may win U.S. approval of $3 billion eczema drug by March

French drugmaker Sanofi (SASY.PA) and its U.S. partner Regeneron Pharmaceuticals (REGN.O) could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March.

Sanofi badly needs new products to make up for flagging sales in its diabetes business, where its top-seller Lantus faces growing competition.

Read more

To category page

Loading...